Gossamer Bio Inc. (NASDAQ: GOSS) reported Q4 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $7.52 million.

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.